FDA-approved kinase inhibitors in PROTAC design, development and synthesis

FDA-approved kinase inhibitors represent a rapidly growing class of targeted therapies with proven clinical success in oncology. However, their occupancy-driven mode of action is often associated with resistance, off-target effects, and incomplete inhibition. Proteolysis-Targeting Chimaeras (PROTACs...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Kacper Kossakowski, Alina Cherniienko, Lucjusz Zaprutko, Anna Pawełczyk
Format:	Artigo
Sprog:	Inglês
Udgivet:	Taylor & Francis Group 2025-12-01
Serier:	Journal of Enzyme Inhibition and Medicinal Chemistry
Fag:	Proteolysis-targeting chimaera (PROTAC) targeted protein degradation (TPD) kinase inhibitor FDA-approved drug cancer
Online adgang:	https://www.tandfonline.com/doi/10.1080/14756366.2025.2542357
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!